#Sweden #Stockholm #dermatology #Nevisense #SciBase

SciBase Reports Significant Growth in Q1 2026 Despite Financial Losses and Challenges

SciBase Holding AB recently released its interim report for the first quarter of 2026, revealing remarkable sales growth alongside ongoing challenges in profitability. The report, covering January 1 to March 31, 2026, reflects the company’s resilient operations as it navigates a competitive landscape in medical technology, particularly in dermatology.

Financial Performance Overview

Net sales for the quarter reached TSEK 14,278, marking a substantial 61% increase compared to the same period last year, with currency effects accounting for an impressive 80% growth. However, the company posted a net loss after tax of TSEK 24,490, slightly higher than the TSEK 20,682 loss reported the previous year. The loss per share improved to SEK 0.03, a decrease from SEK 0.07 in Q1 2025, indicating better management of shareholdings amidst challenging market conditions.

Despite these losses, cash flow from operating activities remained negative, at TSEK 26,573, but this was only a marginal increase from TSEK 26,001 during the same quarter last year. The gross margin decreased significantly to 49.2% from 70.5%, suggesting heightened operational costs and market pressures affecting profitability.

Sales and Market Expansion

The product sales volume of electrodes surged by 70%, totaling 30,460 units sold in the quarter. This rise can be attributed to increased repeat purchases from existing customers, which saw a marked growth of 73%, reflecting customer confidence in SciBase’s offerings. Particularly noteworthy was the performance in the US skin cancer market, which saw a 79% increase, notable for being 109% in local currency, showcasing a strong demand within this crucial segment.

In Germany, SciBase’s skin cancer segment sales remained stable, experiencing a 5% increase in local currency year-on-year. The skin barrier segment experienced an extraordinary growth rate of 1,042%, highlighting enhanced recognition and reliance on SciBase products for various dermatological applications.

Strategic Developments

During this quarter, important strategic decisions were made to fortify the company’s financial standing. SciBase conducted a rights issue that attracted a subscription rate of 96.4%, generating around SEK 80 million before costs, bolstering its operational financial buffer. Furthermore, the successful bid to repurchase 83.9% of the outstanding TO2 warrants demonstrates shareholder commitment and confidence in the company’s direction.

The company announced a crucial clinical study showcasing Nevisense's ability to predict atopic dermatitis in newborns, aiming to improve early disease detection and intervention. Additionally, Dr. Hess, a notable US physician, published findings reinforcing Nevisense's efficacy in enhancing melanoma detection, further solidifying the product’s reputation in the market.

Moreover, Nevisense received recognition in the NCCN Guidelines for Melanoma, thereby endorsing its application in melanoma detection, which could pave the way for broader insurance coverage and usage guidelines in clinical practice.

Looking Ahead

Looking beyond Q1, SciBase achieved significant milestones with over 400,000 tests sold globally, highlighting the acceptance and market penetration of its diagnostic solutions. The upcoming Annual General Meeting (AGM) is expected to address shareholder concerns and outline future strategies to minimize losses and maximize growth potential.

In summary, while SciBase faces significant challenges, the first quarter's results indicate substantial growth in sales and product demand amidst financial difficulties. The company's continued commitment to innovation and market expansion in dermatological technology positions it well for the future, making it an entity to watch as it navigates a rapidly evolving industry landscape.

For more information about SciBase and its innovative products, visit their official website at www.scibase.com.